Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
- To determine the objective response rate to trametinib in children with recurrent or refractory juvenile myelomonocytic leukemia (JMML).
- To further define and describe the toxicities of single agent trametinib in children with recurrent or refractory JMML.
II. To further characterize the pharmacokinetics of trametinib in children with recurrent or refractory JMML.
III. To prospectively evaluate mutant allele burden as a marker of disease activity in JMML.
IV. To measure the objective response rate to 12 cycles of trametinib in children with recurrent or refractory JMML.
- To measure the rate of complete responses in children with recurrent or refractory JMML.
VI. To measure the duration of response among responders.
- To describe the distribution of JMML diagnostic criteria in children with recurrent or refractory JMML.
Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up annually for up to 5 years.
Activating RAS Mutation Blasts Under 20 Percent of Bone Marrow Nucleated Cells Blasts Under 20 Percent of Peripheral Blood White Cells Juvenile Myelomonocytic Leukemia Monosomy 7 Neurofibromatosis Type 1 NF1 Gene Mutation PTPN11 Gene Mutation Splenomegaly Leukemia Leukemia, Myelomonocytic, Acute Leukemia, Myelomonocytic, Chronic Neurofibromatoses Neurofibromatosis 1 Neurofibroma Leukemia, Myelomonocytic, Juvenile Monosomy Trametinib Laboratory Biomarker Analysis Pharmacological Study
You can join if…
Open to people ages 1 month to 21 years
- Patients must have had histologic verification of juvenile myelomonocytic leukemia (JMML) at original diagnosis and currently have relapsed or refractory disease; the diagnosis is made based on the following criteria
- JMML category 1 (all of the following): the diagnostic criteria must include all features in category 1 and EITHER (i) one of the features in category 2 OR (ii) two features from category 3 to make the diagnosis
> 1000 (1 x 109/uL) circulating monocytes
- < 20% blasts in the bone marrow or peripheral blood
- Absence of the t(9;22) or BCR/ABL fusion gene
- JMML category 2 (at least one of the following if at least two category 3 criteria are not present):
- Somatic mutation in RAS or PTPN11
- Clinical diagnosis of NF1 or NF1 gene mutation
- Homozygous mutation in CBL
- Monosomy 7
- JMML category 3 (at least two of the following if no category 2 criteria are met):
- Circulating myeloid precursors
White blood cell count, > 10 000 (10 x 109/ uL)
- Increased hemoglobin F for age
- Clonal cytogenetic abnormality
- GM-CSF hypersensitivity
- Patients with refractory or relapsed JMML must have had at least one cycle of intensive frontline therapy or at least 2 cycles of a deoxyribonucleic acid (DNA) demethylating agent with persistence of disease, defined by clinical symptoms or the presence of a clonal abnormality; frontline therapy is defined as one cycle of intravenous chemotherapy that includes of any of the following agents: fludarabine, cytarabine, or any anthracycline but specifically excludes oral 6-mercaptopurine; frontline therapy will also include any conditioning regimen as part of a stem cell transplant; patients who transform to AML at any point with more than 20% blasts are not eligible for this trial
- Patients must have a Lansky or Karnofsky performance status score of >= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment
- Myelosuppressive chemotherapy: patients must have completely recovered from all acute toxic effects of chemotherapy, immunotherapy or radiotherapy prior to study enrollment; at least 14 days must have elapsed since the completion of cytotoxic therapy, with the exception of hydroxyurea
- Note: cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of protocol therapy
- Hematopoietic growth factors: at least 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur
- Biologic (anti-neoplastic agent): at least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur
- Monoclonal antibodies:
- At least 30 days after the completion of any type of immunotherapy, e.g. tumor vaccines
- At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody
- >= 2 weeks must have elapsed since local palliative external radiation therapy (XRT) (small port)
- >= 6 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if traumatic brain injury (TBI) was received
- >= 4 weeks must have elapsed if other substantial bone marrow irradiation was given
- Stem cell transplant or rescue without TBI: no evidence of active graft versus (vs.) host disease and >= 3 months must have elapsed since transplant
- Patients must not be known to be refractory to red blood cell or platelet transfusions
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m2 or a serum creatinine based on age/gender as follows (must be performed within 7 days prior to enrollment):
- Age: Maximum serum creatinine (mg/dL)
- 1 month to < 6 months: 0.4 (male) 0.4 (female)
- 6 months to < 1 year: 0.5 (male) 0.5 (female)
- 1 to < 2 years: 0.6 (male) 0.6 (female)
- 2 to < 6 years: 0.8 (male) 0.8 (female)
- 6 to < 10 years: 1 (male) 1 (female)
- 10 to < 13 years: 1.2 (male) 1.2 (female)
- 13 to < 16 years: 1.5 (male) 1.4 (female)
- >= 16 years: 1.7 (male) 1.4 (female)
- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment)
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN (=< 135 U/L) (for the purpose of this study, the ULN for SGPT is 45 U/L) (must be performed within 7 days prior to enrollment)
- Serum albumin >= 2 g/dL (must be performed within 7 days prior to enrollment)
- Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by multi-gated acquisition (MUGA)
- Corrected QT (by Bazett's formula [QTcB]) interval < 450 msecs
- Patients must be able to swallow tablets or liquid; use of a nasogastric or gastrostomy (G) tube is also allowed
You CAN'T join if...
- Patients who are pregnant or breast-feeding are not eligible for this study as there is yet no available information regarding human fetal or teratogenic toxicities; negative pregnancy tests must be obtained in girls who are post-menarchal; patients of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy; women of childbearing potential should be advised to use effective contraception for 4 months after the last dose of trametinib; trametinib may also potentially be secreted in milk and therefore breastfeeding women are excluded; female patients should not breastfeed during treatment with trametinib, and for 4 months following the last dose; male patients must use a condom during intercourse and agree not to father a child during therapy and for 4 months following discontinuation of trametinib to avoid unnecessary exposure of trametinib to the fetus
- Concomitant Medications
- Corticosteroids: patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
- Note: hydrocortisone used as a pre-medication to prevent transfusion related reactions is not considered a concomitant corticosteroid
- Investigational drugs: patients who are currently receiving another investigational drug are not eligible
- Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible (except patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)
- Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial
- Cardiac medications: any medications for treatment of left ventricular systolic dysfunction
- Patients who have an uncontrolled infection are not eligible
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
- Patients with a history of hepatic sinusoid obstructive syndrome (veno-occlusive disease) within the prior 3 months
- Patients with a history of current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
- Patients with a history of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension)
- Uncontrolled systemic disease(s) such as hypertension or diabetes mellitus; blood pressure must be =< the 95th percentile for age, height, and gender
- History of allergic reaction attributed to compounds of similar chemical or biologic composition to the MEK inhibitor, trametinib
- Patients who are able to swallow capsules or liquid or able to use a nasogastric or G tube are eligible
- UCSF Medical Center-Mission Bay
accepting new patients
San Francisco California 94158 United States
- Children's Hospital of Orange County
accepting new patients
Orange California 92868 United States
Lead Scientist at UC Cancer
- Elliot Stieglitz (ucsf)
Juvenile myelomonocytic leukemia (JMML) is a blood cancer that affects young children and is often difficult to diagnose and treat. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while a rare group get better with very little treatment.
- accepting new patients
- Start Date
- Completion Date
- National Cancer Institute (NCI)
- Phase 2
- Study Type
- Last Updated